Protocol summary

Study aim
Comparison of clomiphene citrate and Cetrotide in IVF (In Vitro Fertilization)cycles to prevent LH surge and pregnancy results.
Design
Clinical trial with control and intervention group, with parallel groups, unblinded, randomized, phase 3 on 68 patients. Randomization will be done by block randomization method.
Settings and conduct
This study will be conducted in the field of infertility treatment on 68 patients referred to the infertility clinic of Alzahra Hospital in Tabriz. Patients will be randomly divided into two groups of 34 people. The control group will receive 0.25 mg/d of sterotide subcutaneously, and the intervention group will receive clomiphene citrate 150 mg daily.
Participants/Inclusion and exclusion criteria
Infertile women with the age of 20-40 years will enter the study and in case of endometriosis grade 3 and 4, they will be prohibited from entering the study.
Intervention groups
In the intervention group, clomiphene citrate 150 mg will be prescribed to the patient daily from the time of observation of the follicle with a diameter of 13 mm. Follicular monitoring will be done on the fifth to sixth day of stimulation by ultrasound. When 3 follicles above 17 mm are observed, 10,000 international units of hCG will be prescribed for final egg maturation and ovulation.In the control group, the stimulation will be done by gonadotropin from the third day of menstruation. A transvaginal ultrasound will be performed 5-6 days after gonadotropin stimulation, and then repeated every 2-3 days according to the patient's condition. Cetrotide 0.25 mg/d will be injected subcutaneously when the follicular diameter reaches 13-14 mm. When 3 follicles with a diameter greater than 17 mm are observed, 10,000 IU of hCG will be used for final egg maturation and ovulation stimulation.
Main outcome variables
Pegnancy outcome were considered as the main outcome.

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20240806062668N1
Registration date: 2024-08-07, 1403/05/17
Registration timing: prospective

Last update: 2024-08-07, 1403/05/17
Update count: 0
Registration date
2024-08-07, 1403/05/17
Registrant information
Name
Parvin Hakimi
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 41 3557 1113
Email address
hakimip@tbzmed.ac.ir
Recruitment status
recruiting
Funding source
Expected recruitment start date
2024-08-10, 1403/05/20
Expected recruitment end date
2026-08-16, 1405/05/25
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison of clomiphene citrate and Cetrotide in IVF (In Vitro Fertilization)cycles to prevent LH surge and pregnancy results.
Public title
Comparison of Clomiphene Citrate and Cetrotide in Fertility Outcomes with Egg Fertilization Method in the Laboratory
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Infertile women aged 40-20 years Antral Follicle Count (AFC) top four on the third day of the menstrual cycle The base FSH less than IU / L15
Exclusion criteria:
Endometriosis grade 3 and 4 Any contraindications for ovarian stimulation
Age
From 20 years old to 40 years old
Gender
Female
Phase
3
Groups that have been masked
No information
Sample size
Target sample size: 68
Randomization (investigator's opinion)
Randomized
Randomization description
The participants will be assigned to two intervention and control groups based on the randomization sequence that will be generated in advance. This sequence is unpredictable and its arrangement is completely random. Block randomization method with 4 and 6 blocks will be used to allocate the samples. In this way, by using the block method random number generation software, the randomization sequence will be produced according to the required sample size for two groups. In the beginning, all the modes in which 2 letters A and B can be put together in blocks of 4 and 6 are produced. Then a block will be selected randomly and by placement among the blocks, and the arrangement pattern in that block will be used to allocate the participants. Then this block will be placed in the main container and another block will be selected again. All these works will be done with a software called Sealed Envelope. Using this method, concealment will also be observed. The concept of concealment is the unpredictability of assigning people to groups. In fact, the researcher will not be able to predict which group the next person will be in.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee Of Tabriz University Of Medical Sciences
Street address
Third Floor, Number 2 Central Building, Golgasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
5166616471
Approval date
2024-06-24, 1403/04/04
Ethics committee reference number
IR.TBZMED.REC.1403.232

Health conditions studied

1

Description of health condition studied
Infertility
ICD-10 code
N97
ICD-10 code description
Female infertility

Primary outcomes

1

Description
Number of resulted oocytes
Timepoint
The day of oocytes pick up
Method of measurement
Microscopic evaluation

2

Description
Quality of resulted oocytes
Timepoint
The day of oocytes pick up
Method of measurement
Microscopic evaluation

3

Description
chemical pregnancy
Timepoint
2 weeks after IVF and embryo transfer
Method of measurement
serum β-HCG level

Secondary outcomes

1

Description
Implantation
Timepoint
4 weeks after IVF and embryo transfer
Method of measurement
Transvaginal sonography to detect gestational sacs

2

Description
Clinical Pregnancy
Timepoint
6 weeks after embryo transfer
Method of measurement
Detection of gestational sac and fetal heart rate on transvaginal sonography

Intervention groups

1

Description
Intervention group: In the intervention group, clomiphene citrate 150 mg (Aburihan Pharmaceutical Company) will be prescribed to the patient daily from the time of observation of the follicle with a diameter of 13 mm. Follicular monitoring will be done on the fifth to sixth day of stimulation by ultrasound and will be repeated every 2-3 days according to the condition of the patients. Serum levels of progesterone, estradiol, FSH (Follicle Smulating Hormone), and LH (Luteinizing hormone ) will be checked in blood samples on the third day of menstruation.Progesterone in the middle of the cycle And LH will be measured with ultrasound In addition, LH, progesterone, and estradiol will be measured on the day of the hCG (human chorionic gonadotropin) injection. When 3 follicles above 17 mm are observed, 10,000 international units of hCG will be prescribed for final egg maturation and ovulation.
Category
Treatment - Drugs

2

Description
Control group: In the control group, which will receive the stimulation protocol of antagonists, the stimulation will be done by gonadotropin from the third day of menstruation. A transvaginal ultrasound will be performed 5-6 days after gonadotropin stimulation, and then repeated every 2-3 days according to the patient's condition. Cetrotide 0.25 mg/d will be injected subcutaneously when the follicular diameter reaches 13-14 mm. When 3 follicles with a diameter greater than 17 mm are observed, 10,000 IU of hCG will be used for final egg maturation and ovulation stimulation. The stimulation protocol in both groups and the drugs used will be the same, which includes the following drugs: Letrozole 2.5 mg tablets 2 times a day, which will start from the third day of the menstrual cycle Sinal F ampoule 75 to 300 daily units, the dose of the drug will be selected depending on the patient's conditions, which will start from the fifth day of the menstrual cycle. 1 HMG ampoule daily that will start on the seventh day of the menstrual cycle Then, in the control group, the follicle with a diameter of 13 mm will be started with sterotide, and in the intervention group, clomiphene will be started. All the above medicines will continue until the follicle is observed with a diameter of 17 mm (until the day of hCG injection). The aspirated eggs will be fertilized by ICSI (intracytoplasmic sperm injection) in laboratory conditions.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Alzahra Hospital
Full name of responsible person
Dr.Parvin Hakimi
Street address
Alzahra Hospital, South Artesh St.,Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5138665793
Phone
+98 41 3553 9161
Email
lahroudin@gmail.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Vice chancellor for Research, Tabriz University Of Medical Sciences
Full name of responsible person
Dr.Parviz Shahabi
Street address
No. 2 Central Building, Tabriz University of Medical Sciences, Golgasht Street, Tabriz
City
Tabriz
Province
East Azarbaijan
Postal code
5138665793
Phone
+98 41 3335 7310
Email
research-vice@tbzmed.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Vice chancellor for Research, Tabriz University Of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Hakimi
Position
Assistant Professor of Obstetrics Gynecology
Latest degree
Subspecialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Tabriz University Of Medical Sciences, Golgasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
5138665793
Phone
+98 35519161
Email
lahroudin@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Hakimi
Position
Assistant Professor of Obstetrics Gynecology
Latest degree
Subspecialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Tabriz University Of Medical Sciences, Golgasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
5138665793
Phone
+98 35519161
Email
lahroudin@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Parvin Hakimi
Position
Assistant Professor of Obstetrics Gynecology
Latest degree
Subspecialist
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Tabriz University Of Medical Sciences, Golgasht Street
City
Tabriz
Province
East Azarbaijan
Postal code
5138665793
Phone
+98 35519161
Email
lahroudin@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...